ACE-031 regulatory update

FDA granted Orphan Drug designation for Acceleron's ACE-031 to treat Duchenne muscular dystrophy (DMD). The myostatin (GDF8) inhibitor is in Phase II testing and has Fast Track designation from FDA f...